



## COMPANY OVERVIEW

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing REL-1017 (dextromethadone) in multiple indications. RELM-1017 is in Phase 2 for treatment resistant depression and preclinical testing for additional indications. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs.

## MANAGEMENT TEAM

**Sergio Traversa**  
Chief Executive Officer and Interim  
Chief Financial Officer

**Dr. Ottavio Vitolo**  
Senior Vice President, Head of R&D and  
Chief Medical Officer

## RECENT NEWS

[Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels](#)

Oct 2 2018, 8:00 AM EDT

## RELMADA THERAPEUTICS, INC.

750 Third Avenue  
9th Floor  
New York, NY 10017  
US

## STOCK OVERVIEW

Symbol	RLMD
Exchange	OTCQB
Market Cap	15.06m
Last Price	\$1.20
52-Week Range	\$0.61 - \$1.94

## INVESTOR RELATIONS

Relmada Therapeutics, Inc.  
Michael Bell  
750 Third Avenue  
9th Floor  
New York, NY 10017  
T: 212-848-9401  
[mbell@relmada.com](mailto:mbell@relmada.com)

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.